Bicalutamide-associated hallucinations in a metastatic prostate cancer patient: A case report
Küçük Resim Yok
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Sage Publications Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Introduction Bicalutamide is widely used in the treatment of prostate cancer. Among its side effects, central nervous system disorders are relatively rare, and the information about bicalutamide-associated hallucinations is limited. Case report We report an uncommon case of a patient with metastatic prostate cancer, who had hallucinations due to the use of bicalutamide. Management and outcome The patient accepted to receive only hormonal therapy (bicalutamide and leuprolide acetate). But he developed hallucinations due to bicalutamide use. His hallucinations disappeared after discontinuation of bicalutamide. A good response was obtained with the use of luteinizing hormone-releasing hormone agonist monotherapy. Discussion The pathophysiology of bicalutamide-induced hallucinations is unclear. We hypothesize that antiandrogens can indirectly cause hallucinations through changes in plasma testosterone and cerebral reelin expression. Additionally, luteinizing hormone-releasing hormone agonist monotherapy is a good option in metastatic prostate cancer patients who have intolerable side effects due to the use of antiandrogens.
Açıklama
Anahtar Kelimeler
Bicalutamide, Hallucinations, Prostate Cancer, Androgen Deprivation Therapy, Reelin
Kaynak
Journal Of Oncology Pharmacy Practice
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
26
Sayı
4
